CN110664754B - 一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 - Google Patents
一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 Download PDFInfo
- Publication number
- CN110664754B CN110664754B CN201911064958.6A CN201911064958A CN110664754B CN 110664754 B CN110664754 B CN 110664754B CN 201911064958 A CN201911064958 A CN 201911064958A CN 110664754 B CN110664754 B CN 110664754B
- Authority
- CN
- China
- Prior art keywords
- glutamic acid
- metformin
- carboxyl
- cyclic anhydride
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003105 metformin Drugs 0.000 title claims abstract description 70
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000000693 micelle Substances 0.000 title claims abstract description 45
- 229920002643 polyglutamic acid Polymers 0.000 title claims abstract description 40
- 108010020346 Polyglutamic Acid Proteins 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 33
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims abstract description 11
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims abstract description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 51
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 30
- 238000006116 polymerization reaction Methods 0.000 claims description 30
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000007795 chemical reaction product Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 20
- 238000001816 cooling Methods 0.000 claims description 19
- -1 N, N-dimethyl carbamimidoyl Chemical group 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- 229930012538 Paclitaxel Natural products 0.000 claims description 15
- 229960001592 paclitaxel Drugs 0.000 claims description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 15
- 229920001400 block copolymer Polymers 0.000 claims description 13
- 238000004821 distillation Methods 0.000 claims description 13
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 12
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 12
- 229960001237 podophyllotoxin Drugs 0.000 claims description 12
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 150000008064 anhydrides Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 abstract description 27
- 239000000463 material Substances 0.000 abstract description 20
- 238000005538 encapsulation Methods 0.000 abstract description 13
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 7
- 238000011068 loading method Methods 0.000 abstract description 3
- 238000006482 condensation reaction Methods 0.000 abstract 2
- 238000012661 block copolymerization Methods 0.000 abstract 1
- 230000002140 halogenating effect Effects 0.000 abstract 1
- JKEMAHLSSQQCDX-UHFFFAOYSA-N n,n-bis(methylamino)formamide Chemical compound CNN(NC)C=O JKEMAHLSSQQCDX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 230000026030 halogenation Effects 0.000 description 11
- 238000005658 halogenation reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229940009456 adriamycin Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 229910006124 SOCl2 Inorganic materials 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101100242814 Caenorhabditis elegans parg-1 gene Proteins 0.000 description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polyamides (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
包封率(%) | |
实施例1 | 88% |
实施例2 | 78% |
实施例3 | 83% |
对比例1 | 34% |
对比例2 | 41% |
对比例3 | 29% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911064958.6A CN110664754B (zh) | 2019-11-04 | 2019-11-04 | 一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911064958.6A CN110664754B (zh) | 2019-11-04 | 2019-11-04 | 一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110664754A CN110664754A (zh) | 2020-01-10 |
CN110664754B true CN110664754B (zh) | 2021-07-02 |
Family
ID=69085609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911064958.6A Active CN110664754B (zh) | 2019-11-04 | 2019-11-04 | 一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110664754B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110694073A (zh) * | 2019-10-21 | 2020-01-17 | 南通大学附属医院 | 一种载药长循环改性纳米蒙脱土材料及其制备方法 |
CN114939068B (zh) * | 2022-06-28 | 2023-04-21 | 四川大学 | 无定形磷酸钙复合材料及其制备方法、在口腔中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101869713A (zh) * | 2000-08-22 | 2010-10-27 | 希拉有限责任公司 | 活性物质的输送系统和活性物质的保护和施用方法 |
US8119102B1 (en) * | 2005-01-04 | 2012-02-21 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
CN107106596A (zh) * | 2014-12-26 | 2017-08-29 | 日本化药株式会社 | 喜树碱类高分子衍生物的药物制剂 |
-
2019
- 2019-11-04 CN CN201911064958.6A patent/CN110664754B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101869713A (zh) * | 2000-08-22 | 2010-10-27 | 希拉有限责任公司 | 活性物质的输送系统和活性物质的保护和施用方法 |
US8119102B1 (en) * | 2005-01-04 | 2012-02-21 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
CN107106596A (zh) * | 2014-12-26 | 2017-08-29 | 日本化药株式会社 | 喜树碱类高分子衍生物的药物制剂 |
Non-Patent Citations (1)
Title |
---|
Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer;Yang Xiong等;《Journal of Controlled Release》;20161110;第244卷;第63-73页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110664754A (zh) | 2020-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ma et al. | Phenylboronic acid-based glucose-responsive polymeric nanoparticles: synthesis and applications in drug delivery | |
CN106727307B (zh) | 一种还原敏感纳米胶束的制备及应用 | |
CN110664754B (zh) | 一种聚谷氨酸接枝二甲双胍立构纳米胶束及其制备方法 | |
CN102516552B (zh) | 一种可降解的酸敏感高分子两亲性阳离子嵌段共聚物与胶束粒子及其制备方法 | |
CN101306196B (zh) | 一种生物降解的键合了血红蛋白分子的纳米粒子及制法 | |
CN110652595B (zh) | 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法 | |
CN110393700A (zh) | F3多肽导向的pamam为核心的肿瘤药物纳米载体的制备与应用 | |
CN111743861B (zh) | 靶向三阴性乳腺癌的低氧响应手性药物胶束及其制备方法 | |
CN104415010A (zh) | 一种含阿霉素的抗肿瘤胶束的制备方法 | |
CN108676156B (zh) | 一种还原响应型abc型嵌段聚合物及其制备方法和应用 | |
KR101788610B1 (ko) | 의약용 단백질의 지속방출을 위한 약물전달체 및 이의 제조방법 | |
CN109400830B (zh) | 一种pH可解离轻度交联聚合物纳米材料及其制备方法和应用 | |
CN107412162B (zh) | 一种提高喜树碱在嵌段共聚物胶束中载药量的方法 | |
CN112675148B (zh) | 一种多功能高效药物递送系统及其制备方法和应用 | |
US11191728B2 (en) | Method of preparing degradable and environment responsive composite microgels | |
CN107744503B (zh) | 酶敏感性两亲性聚酯MePEG-Peptide-PER-CL给药纳米粒的制备方法 | |
CN104415339A (zh) | 一种自组装靶向纳米药物载体胶束 | |
CN105670006A (zh) | 一种聚乙烯醇-聚(丙交酯-乙交酯)接枝共聚物胶束的制备方法 | |
CN105169405A (zh) | 阿霉素类高分子药物的制备方法 | |
CN111110650B (zh) | 一种酶敏感型两亲性聚酯载药纳米粒的制备方法 | |
AU2020104042A4 (en) | Preparation Method and Application of PH-responsive Polysaccharide-bortezomib Nanosphere | |
CN114712518B (zh) | 一种药物缓释载体、缓释制剂及其制备方法 | |
CN113081960B (zh) | 一种可生物降解且具有温敏性的抗肿瘤键合前药及其制备方法 | |
CN104414999A (zh) | 抗肿瘤靶向纳米载药微胶囊的制备方法 | |
CN115531308B (zh) | 一种纳米结晶胶束递药系统及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230505 Address after: Room 801, 85 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Dayu Chuangfu Technology Co.,Ltd. Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240120 Address after: Building 2, No. 3 Juhe Fourth Street, Jufuyuan Industrial Zone, Yujiawu, Tongzhou District, Beijing, 101149 Patentee after: BEIJING SHENGYONG PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: Room 801, 85 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangzhou Dayu Chuangfu Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |